Expansive, Bunda Hospital Managers Fulfill The Target For Hospital Increases In Six Months

JAKARTA - The manager of the Bundamedik Tbk Mother Hospital (BMHS) recorded the addition of four hospitals in six months this year. Among them are RSIA Azzahra Palembang, Citra Harapan Hospital Bekasi, RSIA Pusura Tegalsari Surabaya, and RSAP Paramarta Bandung.

Based on this note, Bundamedik has become an integrated ecosystem that includes nine Bunda Group Hospitals, 10 Morula tube baby clinics, 126 Indonesian Fertility Clinic satellite fertility clinics, 40 IMTB Patology and Genomic Laboratorys, more than 150 Clinical Clinical networks of Smart Clinic primary services, Medical ER Evacuation teams, and IMTB medical tourism services.

Bundamedik President Director Mesha Rizal Sini said, as a company that has been involved for 49 years in the health care sector, the company always prioritizes sustainable business growth strategies driven by integrated and high standardization health services for patients.

"We hope that the expansion of the Bundamedik ecosystem that continues to run quickly can also have the impact of snow balls in presenting standardization of quality health services that are at the forefront and trusted for the wider community," said Mesha in a statement, quoted on Tuesday, September 13.

Mesha said the target for the expansion of the Bundamedik Hospital has been met in six months this year. Meanwhile, Morula IVF and Diagnos will continue their expansion plans for the remainder of 2022.

He added that this significant increase in the number of hospitals was also in line with the increase in non-COVID patients who had started to return to treatment at the hospital, especially for elective surgery. The number of inpatients and outpatients was recorded to have increased by 42 percent and 12 percent (yoy), respectively. For elective surgery, the growth was recorded to have increased by 41 percent.

In line with the increase in the number of hospitals, the bed growth also rose 54 percent from 414 beds in the first semester of 2021 to 639 in the same period this year.

On the same occasion, Bundamedik President Commissioner Ivan Sini said, despite changes in the pandemic situation, the company was always ready with strong fundamentals and careful preparation. The Company remains focused on the three pillars of priority strategies to continue to encourage sustainable business growth during 2022, namely ecosystem expansion, strengthening the company's core business, and deepening strategic partnerships.

"With these three strategies, we are targeting non-Covid revenue growth of 20 percent - 30 percent with growth in EBITDA 1% every year," said Ivan.

Entering the transition period to an endemic accompanied by revenue from normalized COVID-19, the performance of Bundamei's main business line continues to strengthen.

In general, during the first semester of 2022, the company was able to maintain an increase in non-COVID revenue by 9 percent (yoy). When compared to the period before the pandemic, in the first semester of 2019, the company's consolidated revenue during the first semester of 2022 recorded an increase of 55 percent.

In addition, the EBITDA margin during the first semester of 2022 (outside of the diagnosis and COVID-19-related services) rose 1 point to 18 percent (yoy). If you compare it with Net Revenue (deductible medical services), then EBITDA Margin is at 23 percent during the first semester of 2022.